Evidence map›Paper›PMID 35368077›Full record

ArticleBriefings in bioinformatics2022

cSurvival: a web resource for biomarker interactions in cancer outcomes and in cell lines.

Xuanjin Cheng, Yongxing Liu, Jiahe Wang, Yujie Chen, Andrew Gordon Robertson, Xuekui Zhang, Steven J M Jones, Stefan Taubert

Open access · hybridAbstract read
In one paragraph

Article in Briefings in bioinformatics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Two-stage sampling for better survival model performance.BMC medical research methodology · 2025
    Article
  10. Article
  11. Review
  12. Observational
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Integrative systems biology identifiesGastroenterology and hepatology from bed to bench · 2025
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Xuanjin ChengCentre for Molecular Medicine and Therapeutics, The University of British Columbia, Vancouver, British Columbia, Canada.
Yongxing LiuCentre for Molecular Medicine and Therapeutics, The University of British Columbia, Vancouver, British Columbia, Canada.
Jiahe WangCentre for Molecular Medicine and Therapeutics, The University of British Columbia, Vancouver, British Columbia, Canada.
Yujie ChenCentre for Molecular Medicine and Therapeutics, The University of British Columbia, Vancouver, British Columbia, Canada.
Andrew Gordon RobertsonCanada's Michael Smith Genome Sciences Centre at BC Cancer Agency, Vancouver, British Columbia, Canada.
Xuekui ZhangDepartment of Mathematics and Statistics, University of Victoria, Victoria, British Columbia, Canada.ORCID 0000-0003-4728-2343
Steven J M JonesDepartment of Medical Genetics, The University of British Columbia, Vancouver, British Columbia, Canada.
Stefan TaubertCentre for Molecular Medicine and Therapeutics, The University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0002-2432-7257
University of British Columbia · CABC Cancer Agency · CAUniversity of Victoria · CA

Funding

CIHR PJT-153199
6 · The paper itself

Abstract

Survival analysis is a technique for identifying prognostic biomarkers and genetic vulnerabilities in cancer studies. Large-scale consortium-based projects have profiled >11 000 adult and >4000 pediatric tumor cases with clinical outcomes and multiomics approaches. This provides a resource for investigating molecular-level cancer etiologies using clinical correlations. Although cancers often arise from multiple genetic vulnerabilities and have deregulated gene sets (GSs), existing survival analysis protocols can report only on individual genes. Additionally, there is no systematic method to connect clinical outcomes with experimental (cell line) data. To address these gaps, we developed cSurvival (https://tau.cmmt.ubc.ca/cSurvival). cSurvival provides a user-adjustable analytical pipeline with a curated, integrated database and offers three main advances: (i) joint analysis with two genomic predictors to identify interacting biomarkers, including new algorithms to identify optimal cutoffs for two continuous predictors; (ii) survival analysis not only at the gene, but also the GS level; and (iii) integration of clinical and experimental cell line studies to generate synergistic biological insights. To demonstrate these advances, we report three case studies. We confirmed findings of autophagy-dependent survival in colorectal cancers and of synergistic negative effects between high expression of SLC7A11 and SLC2A1 on outcomes in several cancers. We further used cSurvival to identify high expression of the Nrf2-antioxidant response element pathway as a main indicator for lung cancer prognosis and for cellular resistance to oxidative stress-inducing drugs. Altogether, these analyses demonstrate cSurvival's ability to support biomarker prognosis and interaction analysis via gene- and GS-level approaches and to integrate clinical and experimental biomedical studies.

Indexed as

Biomarkers, TumorLung NeoplasmsAdultCell LineChildGene Expression Regulation, NeoplasticHumansSurvival AnalysisBiomarkers, TumorbiomarkerDepMapgenetic interactionsurvival analysisTARGETTCGA

Identifiers

PMID35368077
PMCPMC9116376
OpenAlexW4213415552

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.